Verastem - VSTM STOCK NEWS

Verastem Oncology (Nasdaq: VSTM) announced the grant of stock options and restricted stock units (RSUs) to three new employees as part of their employment acceptance. The company granted 16,250 stock options with an exercise price of $4.07 per share, based on the closing price on July 1, 2021. Additionally, 8,125 RSUs were awarded, vesting at 25% on the anniversary of hire, with the remainder vesting quarterly over three years. This move aligns with Nasdaq Listing Rule 5635(c)(4) and reflects Verastem’s commitment to attracting talent in its cancer treatment development efforts.

Verastem Oncology (Nasdaq: VSTM) has appointed Dr. Paul Bunn and Lesley Solomon to its Board of Directors, enhancing expertise in cancer treatment and business innovation. Dr. Bunn, an esteemed oncologist, has contributed significantly to cancer research, while Ms. Solomon brings over 25 years of experience in healthcare business development. The appointments coincide with the company's ongoing progress, including FDA Breakthrough Therapy designation for the VS-6766 and defactinib combination, aimed at improving treatment for recurrent low-grade serous ovarian cancer.

Verastem, a biopharmaceutical company focused on cancer treatment, announced its participation in the 2021 Jefferies Virtual Healthcare Conference on June 1, 2021, at 4:00 p.m. ET. A live webcast of the presentation will be available on the Company’s website, with an archived version accessible for 30 days post-event. Verastem specializes in developing new medicines targeting critical cancer signaling pathways, aiming to enhance patient quality of life.

Verastem, Inc. (Nasdaq: VSTM) announces that the FDA has granted Breakthrough Therapy designation for its investigational combination of VS-6766, a RAF/MEK inhibitor, with defactinib, a FAK inhibitor. This designation aims to expedite development for patients with recurrent low-grade serous ovarian cancer (LGSOC) after one or more therapies. Preliminary data from the FRAME trial shows a 52% overall response rate. The designation could facilitate quicker access to new treatment options for patients suffering from this challenging cancer type.

Verastem, Inc. (Nasdaq: VSTM) reported a net loss of $15 million for Q1 2021, or $0.09 per share, an improvement from a $38 million loss in Q1 2020. Total revenue decreased to $1 million from $5.1 million year-over-year. Operating expenses also reduced to $15.1 million, primarily due to strategic shifts following the COPIKTRA sale. The company has $127.1 million in cash, indicating a runway until at least 2024 for its ongoing studies on VS-6766 and defactinib targeting recurrent low-grade serous ovarian cancer and KRAS G12V non-small cell lung cancer.

Verastem, Inc. (Nasdaq: VSTM) reported a Q4 2020 revenue of $0.5 million, down from $3.6 million YoY. Despite a net loss of $19.9 million ($0.12/share), they ended 2020 with $147.2 million in cash. The Company launched two Phase 2 studies for its lead candidate VS-6766 in recurrent low-grade serous ovarian cancer and KRAS-G12V mutant non-small cell lung cancer. Operating expenses are projected at $50 million for 2021, and financial guidance indicates funding availability until at least 2024. Overall, the company is optimistic about clinical advancements and strategic positioning.

Verastem, a biopharmaceutical company focused on cancer treatment, will participate in the virtual H.C. Wainwright Global Life Sciences Conference. The fireside chat will be accessible for on-demand listening starting March 9, 2021, at 7:00 a.m. EST. Interested individuals can find the webcast in the 'Media' section of Verastem's website under 'Events & Presentations.'

Verastem's mission is to develop new medicines targeting critical pathways that promote cancer cell survival and tumor growth, with a focus on RAF/MEK and FAK inhibition.

Verastem, Inc. (Nasdaq: VSTM) announced the immediate departure of Chief Medical Officer Frank Neumann, M.D., Ph.D., who is leaving for another opportunity. CEO Brian Stuglik reassured stakeholders that Neumann's exit will not impact the company's strategic goals or ongoing projects, especially in RAS positive cancers. Verastem remains focused on developing innovative treatments to enhance cancer patient care. The company emphasizes its commitment to addressing unmet medical needs amidst ongoing advancements in its drug pipeline.

Verastem, Inc. (Nasdaq: VSTM) announced the grant of stock options and restricted stock units (RSUs) to five new employees as an inducement for their employment, totaling 86,250 options and 43,125 RSUs, with exercise prices set at $2.20 per share. Additionally, Chief Medical Officer Frank Neumann received 350,000 stock options and 150,000 RSUs, with an exercise price of $2.22. Vesting for these awards occurs over four years, contingent on continued service to the company.